Skip to main content

Table 1 Randomized controlled trials of neoadjuvant radiotherapy versus surgery alone for esophageal squamous cell carcinoma

From: Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?

Study Histology SCC (%) Treatment n MS (months) 5-year OS (%) P value
Launois and colleagues [11] SCC 100 NART 40 Gy 77 10 10 NS
    Surgery 57 12 12  
Gignoux and colleagues [12] SCC 100 NART 33 Gy 106 11 11 NS
    Surgery 102 11 10  
Arnott and colleagues [13] AC/SCC 36 NART 20 Gy 90 8 9 NS
    Surgery 86 8 17  
Nygaard and colleagues [14] SCC 100 NART 35 Gy 48   21a NS
    Surgery 41   9a  
Wang and colleagues [15] SCC 100 NART 40 Gy 104   35 NS
    Surgery 102   30  
  1. aThree-year overall survival (OS). AC adenocarcinoma, MS median survival, NART neoadjuvant radiotherapy, NS not significant, SCC squamous cell carcinoma.